产品展示 / products 您的位置:网站首页 > 产品展示 > 细胞库 > 细胞系 > 人肝内胆管癌细胞HuCCT-1
产品分类

Product category

相关文章

Related articles

人肝内胆管癌细胞HuCCT-1

人肝内胆管癌细胞HuCCT-1

简要描述:青旗(上海)生物技术发展有限公司,总部位于上海浦东新区,依托本地高校资源,逐步发展成为以生物技术为主的研发、生产、培训为一体的综合化产业平台,在标准化细胞库建立及细胞药物前端模型方面成果显著。公司生产经营原代细胞、细胞系、ELISA试剂盒、感受态细胞和HPLC检测等科研产品与服务。我们秉承对用户负责的态度,以对科研的高度严谨,以严格的质量控制,为广大生物医学科研用户提供更优质的服务!

更新时间:2021-05-25

厂商性质:生产厂家

浏览次数:569

详情介绍
品牌其他品牌货号BFN60808823
规格T25培养瓶x1 1.5ml冻存管x2供货周期现货
主要用途仅供科研应用领域医疗卫生,生物产业

细胞名称

人肝内胆管癌细HuCCT-1

img1

货物编码

BFN60808823

产品规格

T25培养x1

1.5ml冻存x2

细胞数量

1x10^6

1x10^6

保存温度

37

-198

运输方式

常温保温运输

干冰运输

安全等级

1

用途限制

仅供科   3

 

培养体系

90%DMEM+10%FBS+1%三抗

培养温度

37

二氧化碳浓度

5%

简介

人肝内胆管癌细HuCCT-156岁男性供体。该细胞源JCRB

注释

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: TCGA-110-CL cell line panel.

Doubling time: ~55 hours (at 10th passage in RPMI + 10% FBS), ~74 hours (at 25th passage in RPMI + 0.2% LA) (PubMed=2544546).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Deep exome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

基因突变

Heterozygous for KRAS p.Gly12Asp (c.35G>A) (ClinVar=VCV000012582) (CCLE; Cosmic-CLP).

Heterozygous for MSH6 p.Lys1358fs*2 (c.4071_4072insGATT) (CCLE; Cosmic-CLP).

Homozygous for TP53 p.Arg175His (c.524G>A) (ClinVar=VCV000012374) (CCLE; Cosmic-CLP).

HLA信息

/

STR信息

 

Amelogenin        X,Y

CSF1PO        11,12

D2S1338        17,18

D3S1358        15

D5S818        12,13

D7S820        10,11

D8S1179        10

D13S317        11,13

D16S539        11,12 (Cosmic-CLP; JCRB; RCB; TKG)

9,11,12 (PubMed=25877200)

D18S51        13

D19S433        13

D21S11        31

FGA        20,23

Penta D        10

Penta E        15,18

TH01        7,10

TPOX        8

vWA        18

参考文献

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

 

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

 

PubMed=31077409; DOI=10.1002/hep.30704

Sittithumcharee G., Suppramote O., Vaeteewoottacharn K., Sirisuksakun C., Jamnongsong S., Laphanuwat P., Suntiparpluacha M., Matha A., Chusorn P., Buraphat P., Kakanaporn C., Charngkaew K., Silsirivanit A., Korphaisarn K., Limsrichamrern S., Tripatara P., Pairojkul C., Wongkham S., Sampattavanich S., Okada S., Jirawatnotai S.

Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity.

Hepatology 70:1614-1630(2019)

 

PubMed=31395879; DOI=10.1038/s41467-019-11415-2

Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

Nat. Commun. 10:3574-3574(2019)



留言框

  • 产品:

  • 您的单位:

  • 您的姓名:

  • 联系电话:

  • 常用邮箱:

  • 省份:

  • 详细地址:

  • 补充说明:

  • 验证码:

    请输入计算结果(填写阿拉伯数字),如:三加四=7




Baidu
map